Lexington, Mass.-based Cubist Pharmaceuticals Inc. has completed its acquisition of San Diego’s Trius Therapeutics Inc. for about $704 million upfront.
Cubist, a $4.3 billion market cap company, is acquiring two biotechs with San Diego connections – Trius, and Jersey City, N.J.-based Optimer Pharmaceuticals, which was founded in San Diego but moved cross country in 2012. Cubist said in August that it would pay $535 million for Optimer, but hasn’t yet completed the acquisition.
The companies have yet to comment on whether they will maintain operations in San Diego.
— Meghana Keshavan